Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities

Christian Dejaco, Elisabeth Brouwer, Justin C. Mason, Frank Buttgereit, Eric Lawrence Matteson, Bhaskar Dasgupta

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.

Original languageEnglish (US)
Pages (from-to)578-592
Number of pages15
JournalNature reviews. Rheumatology
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Polymyalgia Rheumatica
Giant Cell Arteritis
Early Diagnosis
Biological Factors
Interleukin-6
Ultrasonography
Epidemiology
Phenotype
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

Giant cell arteritis and polymyalgia rheumatica : current challenges and opportunities. / Dejaco, Christian; Brouwer, Elisabeth; Mason, Justin C.; Buttgereit, Frank; Matteson, Eric Lawrence; Dasgupta, Bhaskar.

In: Nature reviews. Rheumatology, Vol. 13, No. 10, 01.10.2017, p. 578-592.

Research output: Contribution to journalReview article

Dejaco, Christian ; Brouwer, Elisabeth ; Mason, Justin C. ; Buttgereit, Frank ; Matteson, Eric Lawrence ; Dasgupta, Bhaskar. / Giant cell arteritis and polymyalgia rheumatica : current challenges and opportunities. In: Nature reviews. Rheumatology. 2017 ; Vol. 13, No. 10. pp. 578-592.
@article{3b9291ac8e6649de84ccfb7eabe5b4a7,
title = "Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities",
abstract = "The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.",
author = "Christian Dejaco and Elisabeth Brouwer and Mason, {Justin C.} and Frank Buttgereit and Matteson, {Eric Lawrence} and Bhaskar Dasgupta",
year = "2017",
month = "10",
day = "1",
doi = "10.1038/nrrheum.2017.142",
language = "English (US)",
volume = "13",
pages = "578--592",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Giant cell arteritis and polymyalgia rheumatica

T2 - current challenges and opportunities

AU - Dejaco, Christian

AU - Brouwer, Elisabeth

AU - Mason, Justin C.

AU - Buttgereit, Frank

AU - Matteson, Eric Lawrence

AU - Dasgupta, Bhaskar

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.

AB - The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.

UR - http://www.scopus.com/inward/record.url?scp=85030439208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030439208&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2017.142

DO - 10.1038/nrrheum.2017.142

M3 - Review article

C2 - 28905861

AN - SCOPUS:85030439208

VL - 13

SP - 578

EP - 592

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 10

ER -